Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Cancer risk in IBD: how to diagnose and how to manage DALM and ALM.

Neumann H, Vieth M, Langner C, Neurath MF, Mudter J.

World J Gastroenterol. 2011 Jul 21;17(27):3184-91. doi: 10.3748/wjg.v17.i27.3184. Review.

2.

Invasive behavior of ulcerative colitis-associated carcinoma is related to reduced expression of CD44 extracellular domain: comparison with sporadic colon carcinoma.

Mikami T, Yoshida T, Numata Y, Kikuchi M, Araki K, Nakada N, Okayasu I.

Diagn Pathol. 2011 Apr 7;6:30. doi: 10.1186/1746-1596-6-30.

3.

Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy.

Kisiel JB, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ.

Inflamm Bowel Dis. 2012 Feb;18(2):226-35. doi: 10.1002/ibd.21687. Epub 2011 Mar 17.

PMID:
21416564
4.

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.

Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D.

Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):119-30. doi: 10.1002/pds.2046. Epub 2010 Dec 7.

PMID:
21254282
5.

Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study.

Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K; Japanese Society for Cancer of the Colon and Rectum.

Inflamm Bowel Dis. 2011 Mar;17(3):802-8. doi: 10.1002/ibd.21365.

PMID:
20848547
6.

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP; British Society For Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register.

Arthritis Care Res (Hoboken). 2010 Jun;62(6):755-63. doi: 10.1002/acr.20129. Erratum in: Arthritis Care Res (Hoboken). 2010 Oct;62(10):1514.

7.

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.

Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD.

Ann Surg. 2008 Nov;248(5):857-62. doi: 10.1097/SLA.0b013e3181896278.

PMID:
18948815
8.

Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon.

Ullman T, Odze R, Farraye FA.

Inflamm Bowel Dis. 2009 Apr;15(4):630-8. doi: 10.1002/ibd.20766. Review.

9.
10.

Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray.

Watanabe T, Kobunai T, Toda E, Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Yamamoto Y, Hata K, Kojima T, Yokoyama T, Konishi T, Okayama Y, Sugimoto Y, Oka T, Sasaki S, Ajioka Y, Muto T, Nagawa H.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):415-20.

11.

Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm?

Hurlstone DP, Sanders DS, Atkinson R, Hunter MD, McAlindon ME, Lobo AJ, Cross SS, Thomson M.

Gut. 2007 Jun;56(6):838-46. Epub 2006 Nov 29.

12.
13.

The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Eaden JA, Abrams KR, Mayberry JF.

Gut. 2001 Apr;48(4):526-35.

14.
15.

Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms.

Tarmin L, Yin J, Harpaz N, Kozam M, Noordzij J, Antonio LB, Jiang HY, Chan O, Cymes K, Meltzer SJ.

Cancer Res. 1995 May 15;55(10):2035-8.

Items per page

Supplemental Content

Write to the Help Desk